|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abu-Rustum NR, Yashar CM, Bean S, Bradley
K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, et al:
NCCN guidelines insights: Cervical cancer, version 1.2020. J Natl
Compr Canc Netw. 18:660–666. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ebina Y, Mikami M, Nagase S, Tabata T,
Kaneuchi M, Tashiro H, Mandai M, Enomoto T, Kobayashi Y, Katabuchi
H, et al: Japan Society of Gynecologic Oncology guidelines 2017 for
the treatment of uterine cervical cancer. Int J Clin Oncol.
24:1–19. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matoda M, Takeshima N, Michimae H, Iwata
T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H,
et al: Postoperative chemotherapy for node-positive cervical
cancer: Results of a multicenter phase II trial (JGOG1067). Gynecol
Oncol. 149:513–519. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li S, Hu T, Chen Y, Zhou H, Li X, Cheng X,
Yang R, Wang S, Xie X and Ma D: Adjuvant chemotherapy, a valuable
alternative option in selected patients with cervical cancer. PLoS
One. 8:e738372013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hosaka M, Watari H, Takeda M, Moriwaki M,
Hara Y, Todo Y, Ebina Y and Sakuragi N: Treatment of cervical
cancer with adjuvant chemotherapy versus adjuvant radiotherapy
after radical hysterectomy and systematic lymphadenectomy. J Obstet
Gynaecol Res. 34:552–556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang H, Yu R, Zhang L, Wang R and Xiao L:
Chemotherapy versus chemoradiotherapy for FIGO stages IB1 and IIA1
cervical squamous cancer patients with lymphovascular space
invasion: A retrospective study. BMC Cancer. 22:2022022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weng D, Xiong H, Zhu C, Wan X, Chen Y,
Wang X, Zhang Y, Jiang J, Zhang X, Gao Q, et al: Adjuvant
chemotherapy versus adjuvant concurrent chemoradiotherapy after
radical surgery for early-stage cervical cancer: A randomized,
non-inferiority, multicenter trial. Front Med. 17:93–104. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang YF, Fan Y, Zhang P, Ruan JY, Mu Y
and Li JK: Cervical cancer recurrence and patient survival after
radical hysterectomy followed by either adjuvant chemotherapy or
adjuvant radiotherapy with optional concurrent chemotherapy: A
systematic review and meta-analysis. Front Oncol. 12:8230642022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ikeda M, Shida M, Shigeta S, Nagase S,
Takahashi F, Yamagami W, Katabuchi H, Yaegashi N, Aoki D and Mikami
M: The trend and outcome of postsurgical therapy for high-risk
early-stage cervical cancer with lymph node metastasis in Japan: A
report from the Japan Society of Gynecologic Oncology (JSGO)
guidelines evaluation committee. J Gynecol Oncol. 32:e442021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsuo K, Nusbaum DJ, Matsuzaki S, Klar M,
Shimada M, Takekuma M and Roman LD: Utilization and outcomes of
adjuvant systemic chemotherapy alone in high risk, early stage
cervical cancer in the United States. Int J Gynecol Cancer.
31:991–1000. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto K, Okamoto A, Isonishi S, Ochiai
K and Ohtake Y: A novel gene, CRR9, which was up-regulated in
CDDP-resistant ovarian tumor cell line, was associated with
apoptosis. Biochem Biophys Res Commun. 280:1148–1154. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen XF, Cai S, Chen QG, Ni ZH, Tang JH,
Xu DW and Wang XB: Multiple variants of TERT and CLPTM1L constitute
risk factors for lung adenocarcinoma. Genet Mol Res. 11:370–378.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pande M, Spitz MR, Wu X, Gorlov IP, Chen
WV and Amos CI: Novel genetic variants in the chromosome 5p15.33
region associate with lung cancer risk. Carcinogenesis.
32:1493–1499. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang S, Wu J, Hu L, Ding C, Kan Y, Shen Y,
Chen X, Shen H, Guo X and Hu Z: Common genetic variants in TERT
contribute to risk of cervical cancer in a Chinese population. Mol
Carcinog. 51 (Suppl 1):E118–E122. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Petersen GM, Amundadottir L, Fuchs CS,
Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA,
Bueno-de-Mesquita HB, Gallinger S, Gross M, et al: A genome-wide
association study identifies pancreatic cancer susceptibility loci
on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 42:224–228.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rothman N, Garcia-Closas M, Chatterjee N,
Malats N, Wu X, Figueroa JD, Real FX, Van Den Berg D, Matullo G,
Baris D, et al: A multi-stage genome-wide association study of
bladder cancer identifies multiple susceptibility loci. Nat Genet.
42:978–984. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao Y, Chen G, Zhao Y, Song X, Chen H,
Mao Y and Lu D: Fine-mapping of a region of chromosome 5p15.33
(TERT-CLPTM1L) suggests a novel locus in TERT and a CLPTM1L
haplotype are associated with glioma susceptibility in a Chinese
population. Int J Cancer. 131:1569–1576. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mandour I, Hussein SAM, Essam R and
El-Hossainy MA: Study of genetic variants in chromosome 5p15.33
region in non-smoker lung cancer patients. Adv Respir Med.
88:485–494. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thomsen H, Chattopadhyay S, Hoffmann P,
Nöthen MM, Kalirai H, Coupland SE, Jonas JB, Hemminki K and Försti
A: Genome-wide study on uveal melanoma patients finds association
to DNA repair gene TDP1. Melanoma Res. 30:166–172. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Clarke WR, Amundadottir L and James MA:
CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface
signals for survival and chemoresistance upon ER stress in
pancreatic adenocarcinoma cells. Int J Cancer. 144:1367–1378. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Karami S, Han Y, Pande M, Cheng I, Rudd J,
Pierce BL, Nutter EL, Schumacher FR, Kote-Jarai Z, Lindstrom S, et
al: Telomere structure and maintenance gene variants and risk of
five cancer types. Int J Cancer. 139:2655–2670. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Parashar D, Geethadevi A, McAllister D,
Ebben J, Peterson FC, Jensen DR, Bishop E, Pradeep S, Volkman BF,
Dwinell MB, et al: Targeted biologic inhibition of both tumor
cell-intrinsic and intercellular CLPTM1L/CRR9-mediated
chemotherapeutic drug resistance. NPJ Precis Oncol. 5:162021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sinicrope FA, Ruan SB, Cleary KR, Stephens
LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during
colorectal tumorigenesis. Cancer Res. 55:237–241. 1995.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ni Z, Chen Q, Lai Y, Wang Z, Sun L, Luo X
and Wang X: Prognostic significance of CLPTM1L expression and its
effects on migration and invasion of human lung cancer cells.
Cancer Biomark. 16:445–452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Trezise S, Karnowski A, Fedele PL,
Mithraprabhu S, Liao Y, D'Costa K, Kueh AJ, Hardy MP, Owczarek CM,
Herold MJ, et al: Mining the plasma cell transcriptome for novel
cell surface proteins. Int J Mol Sci. 19:21612018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jia J, Bosley AD, Thompson A, Hoskins JW,
Cheuk A, Collins I, Parikh H, Xiao Z, Ylaya K, Dzyadyk M, et al:
CLPTM1L promotes growth and enhances aneuploidy in pancreatic
cancer cells. Cancer Res. 74:2785–2795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ye Y, Li Z, Kang S, Zhan X, Zhang Y, Xu Y,
Li W, Lang J, Liu P and Chen C: Impact of different postoperative
adjuvant therapies on the survival of early-stage cervical cancer
patients with one intermediate-risk factor: A multicenter study of
14 years. J Obstet Gynaecol Res. 49:1579–1591. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Curtin JP, Hoskins WJ, Venkatraman ES,
Almadrones L, Podratz KC, Long H, Teneriello M, Averette HA and
Sevin BU: Adjuvant chemotherapy versus chemotherapy plus pelvic
irradiation for high-risk cervical cancer patients after radical
hysterectomy and pelvic lymphadenectomy (RH-PLND): A randomized
phase III trial. Gynecol Oncol. 61:3–10. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
James MA, Vikis HG, Tate E, Rymaszewski AL
and You M: CRR9/CLPTM1L regulates cell survival signaling and is
required for Ras transformation and lung tumorigenesis. Cancer Res.
74:1116–1127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
James MA, Wen W, Wang Y, Byers LA, Heymach
JV, Coombes KR, Girard L, Minna J and You M: Functional
characterization of CLPTM1L as a lung cancer risk candidate gene in
the 5p15.33 locus. PLoS One. 7:e361162012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Puskás LG, Mán I, Szebeni G, Tiszlavicz L,
Tsai S and James MA: Novel Anti-CRR9/CLPTM1L antibodies with
antitumorigenic activity inhibit cell surface accumulation, PI3K
interaction, and survival signaling. Mol Cancer Ther. 15:985–997.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grad JM, Zeng XR and Boise LH: Regulation
of Bcl-xL: A little bit of this and a little bit of STAT. Curr Opin
Oncol. 12:543–549. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shimada M, Nishimura R, Nogawa T, Hatae M,
Takehara K, Yamada H, Kurachi H, Yokoyama Y, Sugiyama T and Kigawa
J: Comparison of the outcome between cervical adenocarcinoma and
squamous cell carcinoma patients with adjuvant radiotherapy
following radical surgery: SGSG/TGCU Intergroup Surveillance. Mol
Clin Oncol. 1:780–784. 2013. View Article : Google Scholar : PubMed/NCBI
|
